peer reviewedIn a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes (appropriate titration using a more favourable basal insulin analogue, adding one, two or three rapid-acting insulin analogues, shift to two or three premix insulin injections), adding a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of sodium-glucose cotransporters type 2 (gliflozin), or combining a glucagon-like peptide-1 receptor agonist with basal insulin. The choice should be made according the individual profile and preference of the patient, in a personalized approach, taking into account the advantages and disadv...
peer reviewedGlucagon-like peptide-1 (GLP-1) is a gut hormone secreted in response to the ingestion ...
peer reviewedType 2 diabetes is a complex disease characterized by a dual defect of insulin secretio...
peer reviewedType 1 diabetes (T1D) management is still complex. Some drugs have been proposed as adj...
peer reviewedAfter failure of a monotherapy with metformin, dipeptidyl peptidase-4 inhibitors (glipt...
peer reviewedType 2 diabetes (T2D) is a complex disease with multiple defects, which generally requi...
Insulin therapy, often initiated after hygiene and dietary measures and non-insulin antidiabetics, i...
peer reviewedThe shift to injection therapy, after failure of oral antidiabetic agents, is often con...
peer reviewedAs compared to type 1 diabetes, type 2 diabetes usually requires insulin at a late stag...
peer reviewedBeyond lifestyle changes, the management of type 2 diabetes comprises the administratio...
peer reviewedExenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors o...
peer reviewedType 2 diabetes (T2D) is a complex disease characterized by different pathophysiologica...
peer reviewedGlucovance, recently launched by Merck-Lipha (Glucovance 500 mg/2.5 mg and Glucovance 5...
peer reviewedSitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an en...
peer reviewedADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical t...
peer reviewedManagement of type 1 diabetes essentially relies upon intensive insulin therapy adjuste...
peer reviewedGlucagon-like peptide-1 (GLP-1) is a gut hormone secreted in response to the ingestion ...
peer reviewedType 2 diabetes is a complex disease characterized by a dual defect of insulin secretio...
peer reviewedType 1 diabetes (T1D) management is still complex. Some drugs have been proposed as adj...
peer reviewedAfter failure of a monotherapy with metformin, dipeptidyl peptidase-4 inhibitors (glipt...
peer reviewedType 2 diabetes (T2D) is a complex disease with multiple defects, which generally requi...
Insulin therapy, often initiated after hygiene and dietary measures and non-insulin antidiabetics, i...
peer reviewedThe shift to injection therapy, after failure of oral antidiabetic agents, is often con...
peer reviewedAs compared to type 1 diabetes, type 2 diabetes usually requires insulin at a late stag...
peer reviewedBeyond lifestyle changes, the management of type 2 diabetes comprises the administratio...
peer reviewedExenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors o...
peer reviewedType 2 diabetes (T2D) is a complex disease characterized by different pathophysiologica...
peer reviewedGlucovance, recently launched by Merck-Lipha (Glucovance 500 mg/2.5 mg and Glucovance 5...
peer reviewedSitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an en...
peer reviewedADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical t...
peer reviewedManagement of type 1 diabetes essentially relies upon intensive insulin therapy adjuste...
peer reviewedGlucagon-like peptide-1 (GLP-1) is a gut hormone secreted in response to the ingestion ...
peer reviewedType 2 diabetes is a complex disease characterized by a dual defect of insulin secretio...
peer reviewedType 1 diabetes (T1D) management is still complex. Some drugs have been proposed as adj...